Difference between revisions of "Chlorambucil (Leukeran)"
Jump to navigation
Jump to search
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Nitrogen mustard, alkylating agent. Interferes with DNA replication and induces apoptosis through accumulation of p53 in the cytosol and downstream activation of the apoptosis promoter Bax.<ref name="insert">[ | + | Class/mechanism: Nitrogen mustard, alkylating agent. Interferes with DNA replication and induces apoptosis through accumulation of p53 in the cytosol and downstream activation of the apoptosis promoter Bax.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=967ed3ff-d99b-41e8-b768-dfb586d3d9a6 Chlorambucil (Leukeran) package insert]</ref><ref>[[Media:Chlorambucil.pdf | Chlorambucil (Leukeran) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Line 15: | Line 15: | ||
==Patient drug information== | ==Patient drug information== | ||
− | *[ | + | *[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=967ed3ff-d99b-41e8-b768-dfb586d3d9a6 Chlorambucil (Leukeran) package insert]<ref name="insert"></ref> |
*[http://chemocare.com/chemotherapy/drug-info/chlorambucil.aspx Chlorambucil (Leukeran) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/chlorambucil.aspx Chlorambucil (Leukeran) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/chlorambucil.aspx Chlorambucil (Leukeran) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/chlorambucil.aspx Chlorambucil (Leukeran) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/chlorambucil-patient-drug-information Chlorambucil (Leukeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/chlorambucil-patient-drug-information Chlorambucil (Leukeran) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/chlorambucil-patient-drug-information Chlorambucil (Leukeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/chlorambucil-patient-drug-information Chlorambucil (Leukeran) patient drug information (UpToDate)]</ref> |
Revision as of 17:09, 27 May 2021
General information
Class/mechanism: Nitrogen mustard, alkylating agent. Interferes with DNA replication and induces apoptosis through accumulation of p53 in the cytosol and downstream activation of the apoptosis promoter Bax.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic lymphocytic leukemia
- Hodgkin lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Chlorambucil (Leukeran) package insert[1]
- Chlorambucil (Leukeran) patient drug information (Chemocare)[3]
- Chlorambucil (Leukeran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 3/18/1957: Initial FDA approval
- 11/13/2003: (earliest label available on Drugs@FDA) indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation.
Also known as
- Brand names: Chloraminophene, Chlorambusil, Chlorobutin, Chlorbutin, Leukeran, Linfoxan
References
Categories:
- Drugs
- Oral medications
- Nitrogen mustards
- Alkylating agents
- Chronic lymphocytic leukemia medications
- Hodgkin lymphoma medications
- Follicular lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Waldenström macroglobulinemia medications
- FDA approved in 1957
- WHO Essential Cancer Medicine